Oppenheimer lowered the firm’s price target on Amrize (AMRZ) to $68 from $70 and keeps an Outperform rating on the shares following quarterly results. The firm remains encouraged by Amrize’s positioning to leverage stronger North America construction demand.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ:
- Amrize upgraded to Buy from Hold at Vertical Research
- Amrize reports Q1 EPS (16c), consensus (14c)
- Amrize reaffirms FY26 revenue view $12.29B-$12.52B, consensus $12.42B
- Amrize lifts Q1 revenue, boosts shareholder returns and reaffirms 2026 outlook
- Amrize shareholders approve all proposals at General Meeting